Podgoršek, Eva http://orcid.org/0009-0003-4101-4353
Mehra, Niven http://orcid.org/0000-0002-4794-1831
van Oort, Inge M. http://orcid.org/0000-0002-8002-1869
Somford, Diederik M. http://orcid.org/0000-0002-5277-6586
Boerrigter, Emmy http://orcid.org/0000-0002-3041-6774
van Erp, Nielka P. http://orcid.org/0000-0003-1553-178X
Article History
Accepted: 23 May 2023
First Online: 17 July 2023
Declarations
:
: No sources of funding were used to assist in the preparation of this review.
: Eva Podgoršek, Niven Mehra, Emmy Boerrigter, Inge M van Oort, Diederik M. Somford and Nielka P. van Erp have no conflicts of interest that are directly relevant to the content of this review. Niven Mehra has attended advisory boards of MSD Oncology, Janssen-Cilag, Astellas and AstraZeneca, received travel compensation from Astellas, Roche, Bristol-Myers Squibb, MSD Oncology and Janssen-Cilag and received research funding from Pfizer, Janssen-Cilag, Astellas, Sanofi, Roche and AstraZeneca. Inge M. van Oort has attended advisory boards for Astellas, Janssen-Cilag, Bayer and MSD, has received speaker fees from Bayer, research funding from Astellas, Janssen-Cilag and Bayer and travel compensation from Astellas and Bayer. Diederik M. Somford has attended advisory boards for Astellas, Janssen-Cilag and Bayer and has received speaker fees from Bayer and research funding from Astellas, Janssen-Cilag and Bayer. Nielka P. van Erp has received research funding from Astellas and Ipsen.
: Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Eva Podgoršek, Emmy Boerrigter, and Nielka van Erp were involved in the obtaining, analysis and/or interpretation of data. Eva Podgoršek was involved in the drafting of the manuscript. Niven Mehra, Inge M. van Oort, Diederik M. Somford, Emmy Boerrigter, and Nielka P. van Erp were involved in critical revisions of the manuscript for important intellectual content. All authors were involved in the approval of the final version.